EUVIMEDEUVIMED entdecken
Open Access

Design and Implementation of a Multi‐Center Trial of 129 Xe Gas Exchange MRI and MRS to Evaluate Longitudinal Progression of COPD

Bastiaan Driehuys iD, Shuo Zhang, Aryil Bechtel, Andrew D Hahn iD, Guilhem Collier, Peter J Niedbalski, Yuh-Chin Huang, Zackary I Cleveland, Matthew M Willmering, John P Mugler, Jaime Mata, Yun Michael Shim und 16 weitere

Journal of Magnetic Resonance Imaging · 2025

DOI: 10.1002/jmri.29769 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Magnetic Resonance Imaging, 2025. Verfasst von Bastiaan Driehuys und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Pulmonary Disease, Chronic Obstructive, Xenon Isotopes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIEHS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MR imaging holds the potential to enhance drug development efficiency by de‐risking early phase studies and increasing confidence in results. It can improve patient selection, increase repeatability, and provide greater sensitivity to change, thereby enabling smaller, faster clinical trials. For trials in the pulmonary space, hyperpolarized 129 Xe MRI is appealing because it provides 3‐dimensional imaging of pulmonary ventilation and gas exchange in a brief, non‐invasive exam. Metrics derived from 129 Xe MRI may be more sensitive to disease progression than conventional lung function assessments and may thus provide a valuable means to evaluate numerous novel pharmacologic and biologic therapies now in development. However, despite the acute need for better patient selection and for prognostic and monitoring biomarkers, 129 Xe MR imaging is not yet widely utilized in pulmonary drug development, partly because such trials must be conducted at multiple centers to enroll enough participants. Thus, incorporating 129 Xe MRI requires broader dissemination, harmonized image acquisition protocols, standardized dose delivery, visualization, and quantification. Multi‐site trials must also be able to operate across all major MRI vendor platforms and diverse software/hardware revisions. To this end, the 129 Xe MRI Clinical trials consortium has published a harmonized protocol describing four recommended acquisitions. Here we report on the first industry‐sponsored study to deploy this 129 Xe MRI/MRS protocol in a multi‐center, multi‐platform, multi‐national study to evaluate longitudinal progression of chronic obstructive pulmonary disease (COPD). We demonstrate the steps necessary to implement standardized 129 Xe‐MRI acquisition techniques across multiple sites and discuss the practices implemented, quality control approaches, and lessons learned for facilitating and accelerating the implementation of future trials that incorporate this technology. Level of Evidence: 5.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Magnetic Resonance ImagingPulmonary Disease, Chronic ObstructiveXenon IsotopesHumansMaleDisease ProgressionImaging, Three-DimensionalLongitudinal StudiesLungMagnetic Resonance SpectroscopyMulticenter Studies as TopicReproducibility of ResultsClinical Trials as Topic

Stichwörter der Autor:innen

129Xe MRIchronic obstructive pulmonary diseaseguidelineslongitudinal

Substanzen

Xenon IsotopesXenon-129

Autor:innen und Institutionen

  • Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA.
  • Department of Radiology, University of Iowa, Iowa City, Iowa, USA.
  • POLARIS, Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
  • Department of Pulmonary, Critical Care, and Sleep of Kansas Medical Center, Kansas City, Kansas, USA.
  • Hoglund Biomedical Imaging Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Department of Medicine, Duke University, Durham, North Carolina, USA.

ORCID-Profile: Bastiaan Driehuys, Andrew D Hahn, Sarah Svenningsen, Sean Fain, Jim M Wild, Laura C Bell, David Mummy

Förderung

  • NHLBI NIH HHS
  • NIEHS NIH HHS
  • NIH HHS
  • Genentech
  • Genentech Foundation
  • National Institutes of Health

Zitieren

APA

Driehuys, B., Zhang, S., Bechtel, A., Hahn, A. D., Collier, G., Niedbalski, P. J., Huang, Y. C., Cleveland, Z. I., Willmering, M. M., Mugler, J. P., Mata, J., Shim, Y. M., Castro, M., Svenningsen, S., Friedlander, Y., Ho, T., Fain, S., Hoffman, E. A., Wild, J. M., …, & Mummy, D. (2025). Design and Implementation of a Multi‐Center Trial of 129 Xe Gas Exchange MRI and MRS to Evaluate Longitudinal Progression of COPD. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.29769

Vancouver

Driehuys B, Zhang S, Bechtel A, Hahn AD, Collier G, Niedbalski PJ, et al. Design and Implementation of a Multi‐Center Trial of 129 Xe Gas Exchange MRI and MRS to Evaluate Longitudinal Progression of COPD. Journal of Magnetic Resonance Imaging. 2025. doi:10.1002/jmri.29769

BibTeX
@article{Driehuys2025,
  author = {Driehuys, Bastiaan and Zhang, Shuo and Bechtel, Aryil and Hahn, Andrew D and Collier, Guilhem and Niedbalski, Peter J and Huang, Yuh-Chin and Cleveland, Zackary I and Willmering, Matthew M and Mugler, John P and Mata, Jaime and Shim, Yun Michael and Castro, Mario and Svenningsen, Sarah and Friedlander, Yonni and Ho, Terence and Fain, Sean and Hoffman, Eric A and Wild, Jim M and Thomen, Robert P and Altes, Talissa and Shammi, Ummul Afia and Harris, Will and Zou, Yixuan and Fernandez Coimbra, Alexandre and Belloni, Paula and Bell, Laura C and Mummy, David},
  title = {Design and Implementation of a Multi‐Center Trial of 129 Xe Gas Exchange MRI and MRS to Evaluate Longitudinal Progression of COPD},
  journal = {Journal of Magnetic Resonance Imaging},
  year = {2025},
  doi = {10.1002/jmri.29769}
}
Kostenlos starten →